Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder.
AUTHORS
Nierenberg
AA ,
McElroy
SL ,
Friedman
ES ,
Ketter
TA ,
Shelton
RC ,
Deckersbach
T ,
McInnis
MG ,
Bowden
CL ,
Tohen
M ,
Kocsis
JH ,
Calabrese
JR ,
Kinrys
G ,
Bobo
WV ,
Singh
V ,
Kamali
M ,
Kemp
D ,
Brody
B ,
Reilly-Harrington
NA ,
Sylvia
LG ,
Shesler
LW ,
Bernstein
EE ,
Schoenfeld
D ,
Rabideau
DJ ,
Leon
AC ,
Faraone
S ,
Thase
ME ,
. The Journal of clinical psychiatry. 2016 1 1; 77(1). 90-9
- PMID: 26845264 [PubMed].
ABSTRACT
Bipolar disorder is among the 10 most disabling medical conditions worldwide. While lithium has been used extensively for bipolar disorder since the 1970s, second-generation antipsychotics (SGAs) have supplanted lithium since 1998. To date, no randomized comparative-effectiveness study has compared lithium and any SGA.
Bipolar disorder is among the 10 most disabling medical conditions worldwide. While lithium has been used extensively for bipolar disorder since the 1970s, second-generation antipsychotics (SGAs) have supplanted lithium since 1998. To date, no randomized comparative-effectiveness study has compared lithium and any SGA.
Tags: Alumni Publications 2016